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accepted April 30,ecause the real beneﬁt of pulmonary valve replacement (PVR) in patients with repaired tetralogy of Fallot who
develop pulmonary insufﬁciency remains unclear, it is necessary to analyze the evidence published around the
world. We performed a systematic review of studies that reported data about the effect of PVR in patients with
repaired tetralogy of Fallot that developed pulmonary insufﬁciency, until December 2012. The variables chosen to
represent the beneﬁt were both right ventricular (RV) and left ventricular measures, QRS duration, and functional
class. The principal summary measures were difference in means with 95% conﬁdence interval and p values
(considered statistically signiﬁcant when p < 0.05). The differences in means were combined across studies with
the weighted DerSimonian-Laird random effects model. Meta-analysis, sensitivity analysis, and meta-regression
were completed with the software Comprehensive Meta-Analysis (version 2, Biostat, Inc., Englewood, New Jersey).
Forty-eight studies involving 3,118 patients met the eligibility criteria. The pooled 30-day mortality was 0.87%
(47 studies; 27 of 3,100 patients); the pooled 5-year mortality was 2.2% (24 studies; 49 of 2,231 patients); the
pooled 5-year re-PVR was 4.9% (15 studies; 88 of 1,798 patients). The results of this meta-analysis demonstrate
that after PVR: 1) the RV experiences improvement of its volumes and function; 2) the left ventricle experiences
improvement of its function; 3) QRS duration decreases; 4) symptoms improve; 5) pre-operative RV geometry
modulates the effect of PVR; and 6) there is important heterogeneity of the effects among the studies, and few
publication biases. In conclusion, PVR seems to be a positive approach in the analyzed scenario. (J Am Coll Cardiol
2013;62:2227–43) ª 2013 by the American College of Cardiology FoundationRationale
The current indications of pulmonary valve replacement
(PVR) for pulmonary insufﬁciency in patients with repaired
tetralogy of Fallot (TOF) according to the most recent
guidelines (1,2) are based overall on the presence of symp-
toms (Class I). In asymptomatic patients, the indications are
restricted to the following situations: decrease in exercise
tolerance according to objective tests; right ventricular (RV)
function and size deterioration; presence of sustained atrialn of Cardiovascular Surgery of Pronto Socorro Cardiológico de
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2013.and/or ventricular arrhythmias; tricuspid regurgitation (at
least moderate); and RV outﬂow tract obstruction (Class
IIa).
Despite recommendation classes, the levels of evidence
still remain low (level B and C). Therefore, it is necessary to
review the current state of published medical data with
regard to this subject.Objectives
This analysis was planned in accordance with current guide-
lines for performing comprehensive systematic reviews and
meta-analysis with regression, including the PRISMA
(Preferred Reporting Items for Systematic reviews Meta-
Analyses) (3) and MOOSE (Meta-analysis Of Ob-
servational Studies in Epidemiology) (4) guidelines for
randomized and nonrandomized studies, respectively. We
aimed to determine the outcomes after PVR and its effect
Abbreviations
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LVEF = left ventricular
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MRI = magnetic resonance
imaging
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PRF = pulmonary
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PVR = pulmonary valve
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2228on indexed ventricular volumes,
ventricular function, functional
class, and QRS duration in pe-
diatric and adult patient pop-
ulations after operative repair of
TOF.
Methods
Eligibility criteria. With the
PICOS (Participants, Interven-
tions,ComparisonsandOutcomes)
strategy, studies were considered if:
1) the population comprised pa-
tients with total repaired TOF that
developed at least moderate pul-
monary valve insufﬁciency; 2) pa-
tients were submitted to PVR; 3)
patients were assessed before and
after PVR; 4) outcomes studied
included any of the following:
30-day and 5-year mortality rates,
5-year redo-PVR rate, indexed
right ventricular end-diastolic vol-
ume (RVEDV), indexed right
ventricular end-systolic volume
(RVESV), right ventricular ejec-
tion fraction (RVEF), correctedRVEF, pulmonary regurgitation fraction (PRF), indexed left
ventricular end-diastolic volume (LVEDV), indexed left
ventricular end-systolic volume (LVESV), left ventricular ejection
fraction (LVEF), QRS, RV/LV ratio, New York Heart
Association (NYHA) functional class; and 5) studies were
prospective or retrospective or nonrandomized or random-
ized controlled trials.
Information sources. The following databases were used
(until December 2012): MEDLINE; EMBASE;
CENTRAL/CCTR (Cochrane Controlled Trials Register);
ClinicalTrials.gov; SciELO (Scientiﬁc Electronic Library
Online); LILACS (Literatura Latino Americana em Ciências
da Saúde); Google Scholar; and reference lists of relevant
articles.
Search. We conducted the search with MeSH (Medical
SubjectHeadings) terms (“Tetralogy of Fallot”OR “Tetrallogy,
Fallot’s” OR “Tetralogy, Fallot” OR “Tetralogy, Fallots” OR
“Fallot’s Tetralogy” OR “Fallot Tetralogy” OR “Fallots
Tetralogy”)AND(“PulmonaryValve Insufﬁciency”OR “Valve
Insufﬁciency, Pulmonary” OR “Regurgitation, Pulmonary”
OR “Pulmonary Regurgitation” OR “Valve Regurgitation,
Pulmonary” OR “Valve incompetence, Pulmonary” OR
“Pulmonary Valve Incompetence” OR “Pulmonary Valve
Regurgitation” OR “Regurgitation, Pulmonary Valve” OR
“Insufﬁciency, Pulmonary Valve” OR “Incompetence,
Pulmonary Valve”) AND (“Replacement” OR “Replantation”
OR “Replantations” OR “Surgical Replantation” OR
“Replantation, Surgical” OR “Replantations, Surgical” OR“Surgical Replantations” OR “Reimplantation” OR
“Reimplantations”).
Study selection. The following steps were taken: 1) iden-
tiﬁcation of titles of records through databases searching;
2) removal of duplicates; 3) screening and selection of
abstracts; 4) assessment for eligibility through full-text
articles; and 5) ﬁnal inclusion in study.
One reviewer followed steps 1 to 3. Two independent
reviewers followed step 4 and selected studies. Inclusion or
exclusion of studies was decided unanimously. When there
was disagreement, a third reviewer made the ﬁnal decision.
Data items. The crude endpoints were 30-day mortality
(%), 5-year mortality (%), and 5-year redo-PVR (%). The
following mean values of comparative data were also collected
with regard to pre-operative and post-operative periods:
indexed RVEDV (ml/m2); indexed RVESV (ml/m2); RVEF
(%); corrected RVEF (%); PRF (%); indexed LVEDV (ml/
m2); indexed LVESV (ml/m2); LVEF (%); RV/LV ratio;
QRS duration (ms); and NYHA functional class (mean).
Data collection process. Two independent reviewers
extracted the data. When there was disagreement about
data, a third reviewer (P.E.F.C.) checked the data and made
the ﬁnal decision. From each study, we extracted patient
characteristics, study design, and outcomes.
Risk of bias in individual studies. Included studies were
assessed for the following characteristics: design (prospective
or retrospective); presence of randomization (yes or no);
multicenter enrollment (yes or no); characteristics of
participants (selection bias); characteristics of personnel
(performance bias); outcome assessment (detection bias);
and incomplete outcome data addressed (attrition bias).
Two independent reviewers assessed risk of bias. Agree-
ment between the 2 reviewers was assessed with kappa
statistics for full-text screening and rating of relevance and
risk of bias. When there was disagreement about risk of
bias, a third reviewer (P.E.F.C.) checked the data and made
the ﬁnal decision.
Summary measures. The principal summary measures
were difference in means with 95% conﬁdence intervals and
p values (considered statistically signiﬁcant when p < 0.05).
The meta-analysis was completed with the software Com-
prehensive Meta-Analysis (version 2, Biostat, Inc., Engle-
wood, New Jersey).
Synthesis of results. Forest plots were generated for
graphical presentations of clinical outcomes, and we per-
formed the I2 test and chi-square test for assessment of
heterogeneity across the studies (5). Each study was
summarized by differences in means before and after
PVR. The differences in means were combined across studies
with weighted DerSimonian-Laird random-effects model (6).
Risk of bias across studies. To assess publication bias,
a funnel plot was generated, statistically assessed by Begg
and Mazumdar’s test (7) and Egger’s test (8).
Sensitivity analysis. To evaluate the real RV performance,
it has been suggested that the corrected RVEF measure
Figure 1 Flow Diagram of Studies Included in Data Search
CCTR ¼ Cochrane Controlled Trials Register; LILACS ¼ Literatura Latino Americana em Ciências da Saúde; SciELO ¼ Scientiﬁc Electronic Library Online.
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2229should be used in the pre-operative situation (9) because
pulmonary and tricuspid regurgitationdbeyond shunting
over a residual ventricular septal defectdmight lead to
a compensatory increase in RV cardiac output to maintain
net pulmonary forward ﬂow. Without correction for regur-
gitation and shunting, non-corrected RVEF measure would
overestimate pre-operative RV performance, underestimating
a possible improvement on RV function after PVR.
Taking into consideration this scenario, we decided to
perform an extra analysis to evaluate the changes in RVEF
before and after surgery, considering the pre-PVR corrected
and non-corrected RV function measure.
Meta-regression analysis. Meta-regression analyses were
performed to determine whether the effects of PVR were
modulated by pre-speciﬁed factors. Meta-regression graphs
describe the effect of PVR on the outcome (plotted on the
y-axis) as a function of a given factor (plotted as a mean or
proportion of that factor on the x-axis).
The pre-determined modulating factors to be examined
were: age at TOF repair, time of interval from repair to PVR,
age at PVR, sex, additional procedures, pre-operative indexed
RVEDV, pre-operative indexed RVESV, and PRF changes.Results
Study selection. A total of 5,966 citations were identiﬁed,
of which 72 studies were potentially relevant and retrieved asfull-text. Forty-eight (9–56) publications fulﬁlled our eligi-
bility criteria. Interobserver reliability of study relevance was
excellent (Kappa ¼ 0.80). Agreement for decisions related to
study validity was very good (Kappa ¼ 0.81). The search
strategy can be seen in Figure 1.
Study characteristics. Characteristics of each study are
shown in Table 1. A total of 3,118 patients were
included from studies, dating from 1997 to 2012,
involving patients enrolled from 1960 to 2011. Ten
studies were prospective (20.8%), 1 was randomized (2%),
and 8 were multicenter (16.7%). Most studies consisted
of patients whose mean or median age at PVR was
approximately the ﬁrst and third decade of life and who
were mostly male. Eight (16.7%) studies consisted of an
exclusively pediatric population, 14 (29.2%) were of an
exclusively adult population, and 26 (54.1%) were of
a mixed population. In general, we have observed that
PVR has been indicated in the following situations:
presence of symptoms and/or exercise intolerance during
tests and/or those who had RV impairment, taking into
account imaging data, with more attention given to
cardiac magnetic resonance imaging (MRI) for detecting
RV dilation. The overall internal validity was considered
moderate risk of bias (Table 2).
Synthesis of results. The pooled 30-day mortality was
0.87% (47 studies; 27 of 3,100 patients); the pooled 5-year
mortality was 2.2% (24 studies; 49 of 2,231 patients); the
Table 1 Studies Characteristics
First Author (Ref. #)
Sample
(N)
Sex,
Male
30-Day
Mortality
5-Yr
Mortality
5-Yr
Redo-PVR
Additional
Procedures
Age at Fallot Repair
Mean/Median
(SD or Range)
Time Interval
TOF Repair to PVR
Mean/Median
(SD or Range)
Age at PVR
Mean/Median
(SD or Range)
Chalard et al. (10) 21 47.6 0 ND ND 28.6 5.76 ND ND ND 30.1 14.1
Lee et al. (11) 170 60.6 1.2 1.2 2.9 55.3 2 0.2–44.1 13.8 4.0–27.5 16.7 4.6–60.2
Quail et al. (12) 51 54.9 0 ND ND 17.6 2 0.8–4.7 ND 1.5–2.1 19.6 14.1–24.6
Jang et al. (13) 131 67.9 0 0 3.5 79.4 ND ND 12.5 5.2 14.8 6.7
Tobler et al. (14) 39 59.0 0 ND ND ND 5 1–35 27 14–46 33 20–65
Shiokawa et al. (15) 19 ND 0 0 0 31 5.6 5.4 20.8 10.2 26.1 13.6
Jain et al. (16) 153 47.1 4.6 3.3 ND 20 ND ND ND ND 33 18–74
Batlivala et al. (17) 254 64.2 1.2 1.9 3 83.5 ND ND ND ND 15.6 3.3
Frigiola et al. (18) 73 35.6 0 ND ND ND 3.9 5.2 ND ND 23.6 11.5
Chen PC et al. (19) 227 62.6 0 3 6 74 0.8 0.01–37.0 17.5 0.37–46.13 19.4 0.4–58.1
Chen X-J et al. (20) 161 65.8 1.2 1.2 6 ND ND ND ND ND ND ND
Zubairi et al. (21) 169 55.0 0.6 ND 7 12.4 ND ND 12 0.6–32.1 14.6 0.6–49
Ovcina et al. (22) 24 70.8 0 0 ND 29.2 ND ND ND ND 23.1 6.6
Kane et al. (23) 38 26.3 0 ND ND 59 6.6 10.6 ND ND 33.1 13.2
Geva et al. (24) 64 50.0 0 ND ND 46 1 0–18 20 11.0–47.9 21 11.0–58.0
Shinkawa et al. (25) 73 60.3 0 0 1.3 59 ND ND 19.9 11.6 17.3 2.1–64.4
Scherptong et al. (26) 90 58.9 0 2.2 ND 47 5.8 5.5 ND ND 31.4 10.3
Lindsey et al. (27) 42 64.3 0 0 ND ND 0.73 ND ND ND 8 3
Tsang et al. (28) 16 62.5 0 ND ND ND 6 5 19 9 24 13
Harrild et al. (29) 98 ND 0 6.1 ND 7.1 4.9 6.5 19.7 9.4 24.6 13
Dos et al. (30) 116 51.7 2.5 ND 0.86 95 9 6 ND ND 36 11
Meijboom et al. (31) 17 ND 0 0 ND ND 4.7 3.4 18.6 5.4 27.6 5.8
Graham et al. (32) 93 ND 0 2.1 ND ND 7.8 ND ND ND 27 ND
Knirsch et al. (33) 16 68.8 0 ND ND 25 1.8 0.9 9.9 2.6 11.7 3.5
Frigiola et al. (34) 25 48.0 0 ND ND 95 4.3 6.6 ND ND 21 13
van Huysduynen et al. (35) 30 63.3 0 3.3 ND 33.3 5.7 3.1 ND ND 31.8 9.1
Henkens et al. (36) 27 63.0 0 ND ND 22 5.6 2.8 ND ND 30.8 8.2
Gengsakul et al. (37) 82 50.0 0 2.4 ND 50 9 6.8 18.9 10 27.9 13.1
Oosterhof et al. (38) 71 59.2 0 1.4 4.2 33.8 5 2.7–7.4 IQR ND ND 29 23–37
Ghez et al. (39) 19 52.6 0 ND ND 15.7 ND ND 19.3 9.1 23.9 14
Oosterhof et al. (40) 158 59.5 0 2 9.5 38 6.3 1.5–11.2 ND ND 29 13–45
Kleinveld et al. (41) 10 ND 0 ND ND 70 2.1 0.7 ND ND 11.5 2
Therrien et al. (42) 17 41.2 0 ND ND 88.2 12.1 10.6 25 9 34 12
Buechel et al. (43) 20 ND 0 ND ND 55 1.9 1.1 12 3 13.9 3
Doughan et al. (44) 21 28.6 0 ND ND 44 ND ND 28 5 34 9
van Huysduynen et al. (45) 26 57.7 0 ND ND 38 5 2.8–6.8 IQR ND ND 29.2 24.3–39.4
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2231pooled 5-year re-PVR was 4.9% (15 studies; 88 of 1,798
patients).
The difference in means for indexed RVEDV after PVR
in each study is reported in Figure 2A. Twenty-two studies
reported the data. There was evidence for important
heterogeneity of treatment effect among the studies for
indexed RVEDV. The overall difference in means of
indexed RVEDV showed a signiﬁcant reduction after PVR
(random-effects model: 62.734, SE ¼ 2.591, p < 0.001).
The difference in means for indexed RVESV after PVR
in each study is reported in Figure 2B. Eighteen studies
reported the data. There was evidence for important
heterogeneity of treatment effect among the studies for
indexed RVESV. The overall difference in means of
indexed RVESV showed a signiﬁcant reduction after PVR
(random-effects model: 38.091, SE ¼ 2.420, p < 0.001).
The difference in means for PRF after PVR in each study
is reported in Figure 2C. Fifteen studies reported the data.
There was evidence for important heterogeneity of treatment
effect among the studies for PRF. The overall difference in
means of PRF showed signiﬁcant reduction after PVR
(random-effects model: 38.518, SE ¼ 0.920, p < 0.001).
The difference in means for indexed LVEDV after PVR
in each study is reported in Figure 3A. Fifteen studies re-
ported the data. There was evidence for no heterogeneity of
treatment effect among the studies for indexed LVEDV.
The overall difference in means of indexed LVEDV showed
a signiﬁcant increase after PVR (random-effects model:
6.699, SE ¼ 0.683, p < 0.001).
The difference in means for indexed LVESV after PVR
in each study is reported in Figure 3B. Eleven studies re-
ported the data. There was evidence for important hetero-
geneity of treatment effect among the studies for indexed
LVESV. The overall difference in means of indexed
LVESV showed no signiﬁcant difference after PVR
(random-effects model: 1.437, SE ¼ 0.990, p ¼ 0.147).
The difference in means for LVEF after PVR in each
study is reported in Figure 3C. Seventeen studies reported
the data. There was evidence for important heterogeneity
of treatment effect among the studies for LVEF. The
overall difference in means of LVEF showed signiﬁcant
increase after PVR (random-effects model: 1.821, SE ¼
0.658, p ¼ 0.006).
The difference in means for the RV/LV ratio (indexed
RVEDV/indexed LVEDV) after PVR in each study is
reported in Figure 4A. Six studies reported the data.
There was evidence for important heterogeneity of treatment
effect among the studies for RV/LV ratio. The overall
difference in means of RV/LV ratio showed signiﬁcant
reduction after PVR (random-effects model: 0.922,
SE ¼ 0.094, p < 0.001).
The difference in means for QRS after PVR in each
study is reported in Figure 4B. Twenty studies reported
the data. There was evidence for nonsigniﬁcant heteroge-
neity of treatment effect for QRS among the studies. The
overall difference in means of QRS showed a signiﬁcant
Table 2 Analysis of Risk of Bias: Internal Validity
First Author (Ref. #) Study Design Selection Bias Performance Bias Detection Bias Attrition Bias
Chalard et al. (10) P, R, NM B A A A
Lee et al. (11) NP, NR, NM B B A A
Quail et al. (12) P, NR, NM B B A A
Jang et al. (13) NP, NR, NM B B C C
Tobler et al. (14) NP, NR, NM B B A A
Shiokawa et al. (15) NP, NR, NM B B C A
Jain et al. (16) NP, NR, NM C D D D
Batlivala et al. (17) NP, NR, NM C D D D
Frigiola et al. (18) P, NR, NM C B B A
Chen et al. (19) NP, NR, NM B B B A
Chen et al. (20) NP, NR, NM B B B A
Zubairi et al. (21) NP, NR, NM B D D D
Ovcina et al. (22) P, NR, NM B B A A
Kane et al. (23) NP, NR, NM C B B A
Geva et al. (24) P, R, NM A A A A
Shinkawa et al. (25) NP, NR, NM B D D D
Scherptong et al. (26) P, NR, M B A A A
Lindsey et al. (27) NP, NR, NM B B B A
Tsang et al. (28) NP, NR, NM B C C C
Harrild et al. (29) NP, NR, NM B B B A
Dos et al. (30) NP, NR, NM B D D D
Meijboom et al. (31) NP, NR, NM B B B B
Graham et al. (32) NP, NR, M B D D D
Knirsch et al. (33) NP, NR, NM B B A A
Frigiola et al. (34) P, NR, M B B A A
van Huysduynen et al. (35) NP, NR, NM B B A A
Henkens et al. (36) P, NR, NM B B A A
Gengsakul et al. (37) NP, NR, NM B B A A
Oosterhof et al. (38) P, NR, M B B A A
Ghez et al. (39) NP, NR, M B C C A
Oosterhof et al. (40) NP, NR, M B B A A
Kleinveld et al. (41) NP, NR, M B B A A
Therrien et al. (42) NP, NR, NM B B A A
Buechel et al. (43) P, NR, M B B A A
Doughan et al. (44) NP, NR, NM B B A A
van Huysduynen et al. (45) NP, NR, NM B B A A
van Straten et al. (46) NP, NR, NM C A A A
Borowski et al. (47) NP, NR, NM B D D D
Lim et al. (48) NP, NR, NM B D D D
Cesnjevar et al. (49) NP, NR, NM B D D D
Warner et al. (50) NP, NR, NM B D D D
de Ruijter et al. (51) NP, NR, NM B D D D
Vliegen et al. (9) NP, NR, NM B B A A
Discigil et al. (52) NP, NR, NM B D D D
Therrien et al. (53) NP, NR, M B A A A
Eyskens et al. (54) NP, NR, NM B B A A
Therrien et al. (55) NP, NR, NM A A A A
Yemets et al. (56) NP, NR, NM B D D D
A ¼ risk of bias is low; B ¼ risk of bias is moderate; C ¼ risk of bias is high; D ¼ incomplete reporting; M ¼multicenter; NM ¼ non-multicenter; NP ¼ non-
prospective; NR ¼ non-randomized; P ¼ prospective; R ¼ randomized.
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2232reduction after PVR (random-effects model: 2.861, SE ¼
1.385, p ¼ 0.039).
The difference in means for NYHA after PVR in each
study is reported in Figure 4C. Twenty-six studies reported
the data. There was evidence for important heterogeneity of
treatment effect among the studies for NYHA. The overalldifference in means of NYHA showed a signiﬁcant reduc-
tion after PVR (random-effects model: 0.855, SE ¼
0.097, p < 0.001).
Risk of bias across studies. Funnel plot analysis (Figs. 5 and 6)
disclosed asymmetry around the axis for the treatment
effect in the following outcomes: indexed RVESV; indexed
Figure 2 Forest Plots of Clinical Outcomes of the Right Heart
Pooled difference in means for (A) indexed right ventricular end-diastolic volume (RVEDV), (B) indexed right ventricular end-systolic volume (RVESV), and (C) pulmonary
regurgitation fraction (PRF) after pulmonary valve replacement (PVR). CI ¼ conﬁdence interval.
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Figure 3 Forest Plots of Clinical Outcomes of the Left Heart
Pooled difference in means for (A) indexed LVEDV, (B) indexed LVESV, and (C) left ventricular ejection fraction (LVEF) after PVR. Abbreviations as in Figure 2.
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Figure 4 Forest Plots of Clinical Outcomes
Pooled difference in means for (A) RV/LV ratio, (B) QRS duration, and (C) New York Heart Association (NYHA) functional class after PVR. Abbreviations as in Figure 2.
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2236LVEDV; and QRS. Consequently, we probably have publi-
cation bias related to these outcomes. Publication biases were
not found in the other outcomes.
Sensitivity analysis. The difference in means for non-
corrected RVEF after PVR in each study is reported in
Figure 7A. Eighteen studies reported the data. There was
evidence for important heterogeneity of treatment effect
among the studies for non-corrected RVEF. The overall
difference in means of non-corrected RVEF showed no
signiﬁcant difference after PVR (random-effects model:
1.004, SE ¼ 0.856, p ¼ 0.241).Figure 5 Publication Bias Analysis of Clinical Outcomes by Funnel P
Indexed RVEDV, indexed RVESV, right ventricular ejection fraction (RVEF), indexed RV/LV r
treatment effect in indexed RVESV and QRS (p < 0.05 by Begg and Mazumdar’s test orThe difference in means for corrected RVEF after PVR
in each study is reported in Figure 7B. Only 4 studies re-
ported the data with regard to this outcome. There was
evidence for important heterogeneity of treatment effect
among the studies for corrected RVEF. The overall difference
in means of corrected RVEF showed signiﬁcant increase after
PVR (random-effectsmodel: 21.275, SE¼ 2.913, p< 0.001).
Meta-regression analysis. With regard to pre-operative
indexed RVEDV, we observed statistically signiﬁcant coef-
ﬁcients for changes in post-operative indexed RVEDV
(Fig. 8A), post-operative indexed RVESV (Fig. 8B), andlot Graphic
atio, PRF, and QRS. Funnel plot analysis disclosed asymmetry around the axis for the
Egger’s test). Abbreviations as in Figure 2.
Figure 6 Publication Bias Analysis of Clinical Outcomes by Funnel Plot Graphic
Indexed LVEDV, indexed LVESV, LVEF, and NYHA functional class. Funnel plot analysis disclosed asymmetry around the axis for the treatment effect in indexed LVEDV
(p < 0.05 by Begg and Mazumdar’s test or Egger’s test). Abbreviations as in Figure 4.
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2237NYHA functional class (Fig. 8C). We can observe that the
greater the pre-operative indexed RVEDV in a population
undergoing PVR after TOF repair, the greater the decrease
in post-operative indexed RVEDV and the greater the
decrease in post-operative indexed RVESV but the lower
the improvement in post-operative NYHA functional class.
Additionally, we observed statistically signiﬁcant coefﬁ-
cients for proportion of additional surgical procedures
concomitant to PVR and changes in post-operative indexed
RVEDV (Fig. 8D). We can observe that the greater the
proportion of additional surgical procedures in a population
undergoing PVR after TOF repair, the greater the decrease
in post-operative indexed RVEDV.
Concerning pre-operative indexed RVESV, we observed
statistically signiﬁcant coefﬁcients for changes in post-
operative indexed RVEDV (Fig. 9A) and post-operative
indexed RVESV (Fig. 9B). We can observe that the greater
the pre-operative indexed RVESV in a population under-
going PVR after TOF repair, the greater the decrease in
post-operative indexed RVEDV and the greater the decrease
in post-operative indexed RVESV.
With respect to PRF decrease, we observed statistically
signiﬁcant coefﬁcients for changes in post-operative indexed
RVEDV (Fig. 9C) and post-operative indexed RVESV(Fig. 9D). We can observe that the lower the PRF decrease
in a population undergoing PVR after TOF repair, the
lower the decrease in post-operative indexed RVEDV and
the lower the decrease in post-operative indexed RVESV. In
other words, we could say that the greater the PRF decrease,
the greater the decrease in post-operative indexed RVEDV
and the greater the decrease in post-operative indexed
RVESV.
With regard to age at TOF repair, age at PVR, time from
TOF repair to PVR, and sex, we observed no statistically
signiﬁcant coefﬁcients, which means that these covariates
did not modulate the effect of PVR on outcomes.Discussion
Summary of evidence. To our knowledge, this is the
largest meta-analysis of studies performed to date that
provides incremental value by demonstrating that patients
with repaired TOF who developed pulmonary insufﬁciency
over time after PVR: 1) have a doubtless decrease in PRF;
2) present RV improvement of its indexed volumes but no
improvement in ejection fraction (EF) (taking into account
non-corrected measures); 3) present LV improvement of its
systolic function measured by EF, despite the increasing of
Figure 7 Forest Plots of the Sensitivity Analysis for Noncorrected and Corrected Measures of RVEF
(A) Non-corrected RVEF. (B) Corrected RVEF. Abbreviations as in Figure 5.
Ferraz Cavalcanti et al. JACC Vol. 62, No. 23, 2013
Pulmonary Valve Replacement in Repaired Fallot December 10, 2013:2227–43
2238its indexed diastolic volume and no change of its indexed
systolic volume; 4) have a decrease of QRS duration; and
5) have an improvement of symptoms. Furthermore, if
we consider the corrected RVEF measure, we observe that:
6) in fact, the RV experienced a real improvement of its
systolic function; 7) RVs with greater pre-operative indexed
RVEDV measures presented the best responses in terms of
RV geometry in the post-operative period but were corre-
lated to less improvement of symptoms, despite the
improvement in RV geometry; 8) RVs with greater pre-
operative indexed RVESV measures presented the best
responses in terms of RV geometry in the post-operative
period; 9) hearts with greater PRF decrease measures pre-
sented the best responses in terms of RV geometry in
the post-operative period; 10) populations with greaterproportions of additional procedures presented the best
responses in terms of RV geometry in the post-operative
period; 11) almost all these observations are under important
inﬂuence of heterogeneity of the effects; and 12) we found
virtually no publication bias.
Mortality. Our crude results with regard to pooled 30-day
and 5-year mortality show that the rates seem to be
acceptable, because they are both low. The low reporting of
data about 10-year mortality limits any long-term analysis.
Taking into consideration that almost all the studies re-
ported data with regard to symptomatic patients, these
results must not be used to stimulate aggressive management
in asymptomatic patients.
Effect of PVR on RV. Since the ﬁrst report by Vliegen et al.
(9) about the improvement of RV parameters assessed by
Figure 8 Meta-Regression Analysis
Correlation between a given factor (plotted as a mean or proportion of that factor on the x-axis) and the effect of PVR on the outcome (plotted on the y-axis). Each circle in the plot
represents a study, and the circumference of each circle is proportional to study population size. (A) Pre-PVR–indexed RVEDV and difference in means (indexed RVEDV). (B) Pre-
PVR–indexed RVEDV and difference in means (indexed RVESV). (C) Pre-PVR–indexed RVEDV and difference in means (NYHA). (D) Additional procedures and difference in means
(indexed RVEDV). Abbreviations as in Figure 4.
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2239cardiacMRI, several studies also observed theseﬁndingswith the
volumetric measures before and after PVR to better under-
stand the response of the RV after removal of volume over-
load (10–14,18,19,22,24,27–29,33,34,36,38,39,41–43,46).
Having observed that some ventricles changed more than
others and not all of them reached normal values, Therrien
et al. (42) studied pre-operative parameters to evaluate
the response to PVR and tried to ﬁnd a threshold of volu-
metric measures above which there would be no more
normalization of the ventricle. Only 17 patients were studied
and, taking into account that no patients reached the
normalization if the pre-operative indexed RVEDV was
>170 ml/m2 and RVESV was >85 ml/m2, the author
suggested that PVR should be undertaken before the re-
ported values.
Having concluded that RV volumes decreased on average
28%, Oosterhof et al. (38) tried to ﬁnd a cutoff value for
normalization (57) of the RV volumes in an attempt to
determine the optimal timing for the procedure and
concluded that normalization could be achieved when
pre-operative indexed RVEDV was <160 ml/m2 or
RVESV was <82 ml/m2. It is very important to highlight
that they were not able to ﬁnd a threshold above which RV
volumes did not decrease after surgery.Geva et al. (24) studied a group of 64 patients in
a randomized trial to investigate whether the addition of
surgical RV remodeling to PVR would result in improved
RV function when compared with PVR alone. They analyzed
pre-operative factors associated with optimal (indexed
RVEDV 114 ml/m2 and RVEF 48%) and suboptimal
(indexed RVEDV120 ml/m2 and RVEF45%) outcomes
(RV size and function were taken into account to determine
an optimal post-operative outcome). Pre-operative indexed
RVESV <90 ml/m2 was associated with normalization of
post-operative RV size and function, whereas pre-operative
RVEF <45% was associated with persistent post-operative
RV dilation and dysfunction.
Recently, Quail et al. (12) studied a cohort of 87 patients and
compared intervention versus nonintervention, trying to
establish whether delaying PVR would lead to short-term
progressive deterioration in RV or LV dimensions or func-
tion, and it was observed that total normalization (57) of
RVEDV and RVESV occurred in 64.7% of patients. It is
noteworthy that no absolute upper threshold for normalization
could be determined. Although the tendency for complete
normalization decreased with increasing preoperative volumes,
ventricles portraying very high preoperative RVEDV and
RVESV measures reached normal values after PVR.
Figure 9 Meta-Regression Analysis
Correlation between a given factor (plotted as a mean or proportion of that factor on the x-axis) and the effect of PVR on the outcome (plotted on the y-axis). (A) Pre-PVR–indexed
RVESV and difference in means (indexed RVEDV). (B) Pre-PVR–indexed RVESV and difference in means (indexed RVESV) (C) Difference in means (PRF) and difference in means
(indexed RVEDV). (D) Difference in means (PRF) and difference in means (indexed RVESV). Abbreviations as in Figure 4.
Ferraz Cavalcanti et al. JACC Vol. 62, No. 23, 2013
Pulmonary Valve Replacement in Repaired Fallot December 10, 2013:2227–43
2240We can observe that the evaluation of the RV response
to the PVR seems to be under change, once normalization
of the volumetric measures after procedure is not necessarily
the target. The so-called upper threshold is difﬁcult
to establish, because recent ﬁndings tend to question the
normal values as mentioned by Sarikouch et al. (58) and the
relevance of sex.
The ﬁndings are in accordance with our study. After
evaluating 22 studies (9–14,18,19,22,24,27–29,33,34,36,
38,39,41–43,46) that reported data about pre-operative
and pos-toperative indexed RVEDV and 18 studies (9–14,
18,22,24,28,34,36,38,39,41–43,46) that reported indexed
RVESV, we used the meta-regression and concluded that
populations with greater pre-operative indexed RVEDV
measures presented the best responses in terms of RV
geometry change in the post-operative period. Likewise,
populations with greater pre-operative indexed RVESV
measures presented the best responses in terms of RV
geometry change in the post-operative period. Paradoxically,
populations with the greater pre-operative volumes presented
lesser improvement of symptoms, despite the improvement
in RV geometry.
Although the RVEF measures have been the most re-
ported data among the studies included in this meta-
analysis, these data were not able to demonstrate any
difference after PVR in pooled results. This happened duethe use of non-corrected measure for the presence of
tricuspid and pulmonary regurgitation and residual shunts.
However, when the reported studies used, not only the
uncorrected measure, but the corrected one for these cova-
riates, the difference emerged and revealed the RVEF
improvement. Therefore, the non-corrected measure is not
a reliable tool to assess RVEF before PVR.
Effect of PVR on LV and RV/LV interactions. A recent
publication by Broberg et al. (59), after analysis of 511
patients with repaired TOF, concluded that the left systolic
dysfunction assessed by conventional echocardiography was
present in 21% of patients. When it comes to patients with
previous PVR, the prevalence of LV systolic dysfunction
increased to 52.4%, justifying the current tendency of
studies to focus on LV.
Attention to the left side of the heart after Fallot repair
was ﬁrst given by Kondo et al. (60), who documented latent
LV dysfunction during exercise. Davlouros et al. (61)
assessed 85 adults with cardiac MRI and showed that LV
systolic dysfunction correlated to RV dysfunction, suggest-
ing an unfavorable ventricular  ventricular interaction. This
ﬁnding was also demonstrated by Geva et al. (62).
Left ventricle response after pulmonary insufﬁciency
correction, once RV volume overload is resolved, was docu-
mented by Frigiola et al. (34) studying 25 patients. They
observed an increase in LVEDV after PVR, suggesting a better
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2241LV ﬁlling due to an improved pulmonary forward ﬂow and
a left-to-right shift of interventricular septum. Another study
from the same author (63) with 60 patients showed a signif-
icant reduction in RV volumes and increased LVEDV with
a signiﬁcant improvement in LV systolic function indexes
(EF, effective stroke volume, and effective cardiac output).
The exact mechanism by which there is an improvement
of LV systolic function after PVR might have a physiological
explanation, as pointed out by Geva (64), when the author
refers to the ﬁnding by French physiologist Bernheim in
1910, known as Bernheim’s effect: the recognition of
interdependence between LV and RV function, where
alterations in the size and function of the LV have an
adverse impact on the geometry and function of the RV
(65). After PVR, resembling “reversed Bernheim effect”
(66), the relief of RV volume overload leads to decreased
septal shift toward the LV and augmentation in LV
volumes. Furthermore, there are other mechanisms possibly
involved in ventricular  ventricular interaction: the shared
myoﬁbers, septum, pericardium, and coronary ﬂow.
Therefore, the increase of LV volumes after PVR must
not be misinterpreted as worsening of its performance.
Contrarily, it might signal an improvement. In the scenario
where the enlargement of the RV/LV ratio represents RV
deterioration and a trigger to PVR both for symptomatic
and asymptomatic patients, the decrease of RV volumes and
maybe the increase of LV volumes are goals to be achieved.
Effect of PVR on QRS duration. Tobler et al. (14)
previously documented that QRS enlargement combined
with LVEF reduction had the highest positive and negative
predictive value for sudden cardiac death. Scherptong et al.
(26) have suggested that sudden cardiac death after PVR
relates to the magnitude of change in QRS duration post-
operatively. Our meta-analysis identiﬁed reduction of QRS
duration and LVEF improvement after PVR, which in
combination might mean reduction of long-term mortality.
Obviously, the latter statement is a mere speculation, and
speciﬁc studies are required to conﬁrm it.
Effect of PVR on symptoms. It is essential to reach the
improvement of symptoms when the patients are confronted
with a surgical option, because the presence of symptoms is
stated as criteria for PVR by the current guidelines (1,2) and
is the key point to assessing life quality. Our meta-analysis
showed a clear decrease of symptoms after PVR. However,
the meta-regression method demonstrated that studies
with the greatest means of pre-operative indexed RVEDV
had the greatest decrease in post-operative RV volumes but
the lowest improvement in post-operative NYHA functional
class.
These ﬁndings could lead us to think that we should not
wait until the heart dilates too much, taking into consideration
that it could minimize the beneﬁts on symptoms after PVR.
Role of additional procedures. Additional/concomitant
procedures to PVR were reported in 39 studies and ranged
from 7.1% to 95%. It was not feasible to measure the real
inﬂuence of these procedures through our meta-analysis.Maybe some observed beneﬁts were modulated by these
procedures. This last statement is supported by 1 of our
meta-regressions, which demonstrated a clear correlation
between rate of additional procedures and change in
indexed RVEDV. This fact points to their role in the
elimination of all structural abnormalities (inherent to
TOF repair, residual or recurrent lesions, and acquired
lesions).
The prevalence of structural and functional abnormalities
after primary repair of Fallot is not negligible, as reported
by the INDICATOR (International Multicenter TOF
Registry) (67) cohort. This, in addition to the modulation of
the effect by the prevalence of additional procedures, makes
it unclear whether the beneﬁts observed through PVR are
mostly due to the elimination of pulmonary regurgitation or
due to the resolution of multiple cardiac abnormalities
existing at the time of PVR.
Risk of bias and limitations. This meta-analysis included
data from nonrandomized and/or observational studies,
which reﬂects the “real world,” but they are limited by
treatment bias, confounders, and a tendency to overestimate
treatment effects. Patient selection alters outcome and thus
makes nonrandomized studies obviously less robust.
It is difﬁcult to compare and group these studies, because
of many factors: patients might have been referred for
surgery at different ages and times after primary repair, with
different indications to PVR; different centers have
different surgical routines; so many patients have additional
lesions leading to a high percentage of additional proce-
dures at time of PVR; there is a wide range of valves or
valved conduits; and there is variability of follow-up length
and many techniques used to assess RV function and
volume after PVR.
There are inherent limitations with meta-analyses,
including the use of cumulative data from summary esti-
mates. Patient data were gathered from published data, not
from individual patient follow-up. Access to individual
patient data would have enabled us to conduct further
subgroup analysis and propensity analysis to account for
differences between the treatment groups.Conclusions
Surgical PVR in patients after TOF repair has been asso-
ciated with low 30-day and 5-year mortality rates; accept-
able 5-year re-PVR rate; signiﬁcant decreases in RV volumes
and increase in RV systolic function; increase in both LV
systolic function and volume; decrease in QRS duration; and
improvement in functional class.
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